Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

NCT07429253 | Recruiting Phase 1

• 1 other identifier: CT/ALP/02/2025
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Conditions

Androgenetic Alopecia

Keywords

Secretome; Platelet-Rich Plasma; Androgenetic Alopecia; Trichoscopy

Outcome Measures

Primary Outcomes (2)

• Terminal-to-Vellus Hair Ratio

  The ratio of terminal hair (thick, pigmented hair, diameter \>40 micrometer) to vellus hair (fine hair, diameter \<30 micrometer) in areas of androgenetic alopecia

  Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)

• Hair density

  The number of hairs per specific scalp area was measured in hairs/cm²

  Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)

Study Arms (2)

UC-MSC Secretome

EXPERIMENTAL

Umbilical Cord Mesenchymal Stem Cell-derived Secretome

Biological: Secretome

Platelet-Rich Plasma

EXPERIMENTAL

Platelet-Rich Plasma

Biological: Platelet-Rich Plasma (PRP) Injections

Interventions

Secretome BIOLOGICAL

UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks

UC-MSC Secretome

Platelet-Rich Plasma (PRP) Injections BIOLOGICAL

The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks

Platelet-Rich Plasma

Eligibility Criteria

• Age: 25 Years - 59 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
• Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
• Female patients who are not currently pregnant or breastfeeding.
• Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
• Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
• Patients who are proficient in Indonesian and willing to provide written informed consent.

You may not qualify if:

• Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
• Patients presenting with types of hair loss other than androgenetic alopecia.
• Patients currently undergoing therapy with 5-alpha reductase inhibitors.
• Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
• Patients with active infections and/or active dermatitis on the scalp.
• Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
• History of hypertrophic scarring or blood clotting (coagulation) disorders.
• Patients unable to complete the research procedures in their entirety.

Sponsors & Collaborators

• PT. Prodia Stem Cell Indonesia: lead
• RS Prof. Dr. I.G.N.G Ngoerah: collaborator

Study Sites (1)

Prof. dr. I.G.N.G. Ngoerah Central General Hospital

Denpasar, Bali, 80113, Indonesia

RECRUITING

MeSH Terms

Conditions

Alopecia

Interventions

Secretome; Injections

Condition Hierarchy (Ancestors)

Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Metabolome; Metabolism; Drug Administration Routes; Drug Therapy; Therapeutics

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 17, 2026
• First Posted: February 24, 2026
• Study Start: January 9, 2026
• Primary Completion: June 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: February 24, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)